Annual Costs of Lecanemab Estimated to Be Upwards of $2B

The anti-amyloid agent lecanemab (Leqembi, Eisai) and associated ancillary services could add an estimated $2 to $5 billion annually to Medicare spending, with substantial out-of-pocket costs for Medicare beneficiaries who don’t have supplemental coverage, a new cost analysis suggests. “These additional costs could strain the Medicare program and its beneficiaries, who may face rising premiums to help Medicare pay for […]
» Read more